Malaria P. falciparum vs P. vivax
Direct answer: P. falciparum causes the most severe malaria and requires prompt artemisinin-based treatment; P. vivax is generally less severe but requires additional treatment for dormant liver stages (hypnozoites). Identifying the species guides treatment.
Comparison table
| P. falciparum (Pf) | P. vivax (Pv) | |
|---|---|---|
| Severity | Most severe, can be fatal | Usually less severe |
| Relapse | No liver stage | Yes (hypnozoites) |
| Rapid test marker | HRP2 (or pLDH) | pLDH |
| Treatment | ACT | ACT + primaquine (anti-relapse) |
What each test detects
- Pf: HRP2 antigen (specific to falciparum) or pan pLDH.
- Pv: species-specific pLDH — distinguishes vivax from falciparum.
Testing window
Both are detectable during active parasitemia from symptom onset; low parasite densities can give false negatives.
Strengths
- Species differentiation: guides correct treatment and avoids overtreating with anti-relapse drugs.
Limitations
- HRP2: can persist after treatment; HRP2-deleted strains cause false negatives.
- pLDH: lower sensitivity at very low parasitemia.
False negative / positive considerations
- False negative: low parasitemia, HRP2 deletion.
- False positive: persistent HRP2 after treatment.
Confirmatory testing
Microscopy is the reference for species confirmation and parasitemia quantification.
Procurement considerations
For vivax-endemic regions, stock Pf/Pv or Pf/Pan devices; confirm cut-offs and stability before tender bidding.
Related pages
Which test to choose
Species identification drives treatment — P. falciparum needs ACT, while P. vivax also needs anti-relapse (primaquine). Stock Pf/Pan or Pf/Pv to differentiate.
| Scenario | Recommended |
|---|---|
| Species-guided treatment | Pf/Pv or Pf/Pan |
Sources: WHO malaria treatment and diagnostic guidance.
Last reviewed: 2026-09-12